Veterans Medical Research Foundation Of Sd is located in San Diego, CA. The organization was established in 1987. According to its NTEE Classification (H90) the organization is classified as: Medical Disciplines Research, under the broad grouping of Medical Research and related organizations. As of 09/2023, Veterans Medical Research Foundation Of SD employed 147 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Veterans Medical Research Foundation Of SD is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 09/2023, Veterans Medical Research Foundation Of SD generated $15.9m in total revenue. The organization has seen a slow decline revenue. Over the past 8 years, revenues have fallen by an average of (2.8%) each year. All expenses for the organization totaled $16.4m during the year ending 09/2023. As we would expect to see with falling revenues, expenses have declined by (2.2%) per year over the past 8 years. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2023
Describe the Organization's Mission:
Part 3 - Line 1
TO ENHANCE THE HEALTH OF VETERANS OF ALL GENERATIONS THROUGH RESEARCH AND EDUCATION.
Describe the Organization's Program Activity:
Part 3 - Line 4a
DR. IX - KIDNEY TUBLAR DAMAGE AND DYSFUNCTION IDENTIFY A NOVEL AXIS OF CHRONIC KIDNEY: PATHOLOGIC STUDIES DEMONSTRATE THAT KIDNEY TUBULE INJURY, ATROPHY, AND FIBROSIS ARE COMMON FEATURES OF CHRONIC KIDNEY DISEASE (CKD) AND ARE HIGHLY PREDICTIVE OF PROGRESSION TO DIALYSIS. ESTABLISHED CKD RISK FACTORS INCLUDING HYPERTENSION AND ADVANCED AGE ARE ASSOCIATED WITH TUBULAR INJURY AND FIBROSIS ON BIOPSY. HOWEVER, CURRENT CLINICAL ASSESSMENT OF CKD EVALUATES ONLY GLOMERULAR FUNCTION (GFR) AND GLOMERULAR INJURY (ALBUMINURIA), BUT NOT KIDNEY TUBULAR DYSFUNCTION OR INJURY. THE OVERALL HYPOTHESIS OF THIS APPLICATION IS THAT KIDNEY TUBULAR DYSFUNCTION AND INJURY ARE MEASURABLE CONTRIBUTORS TO CKD PATHOGENESIS AND PROGNOSIS.DYSFUNCTION OF THE KIDNEY TUBULES WILL BE ASSESSED BY THREE INDICES: (1) RENAL TUBULE RESISTANCE TO HORMONE ACTIONS OF FGF23 AND PTH; (2) ACID/BASE HOMEOSTASIS; AND (3) URINE RE-ABSORPTIVE CAPACITY.WE WILL: (1) DETERMINE THE ASSOCIATION OF KIDNEY TUBULAR DYSFUNCTION AND INJURY WITH RISK OF CVD EVENTS, (2) DETERMINE THE ASSOCIATION OF KIDNEY TUBULAR DYSFUNCTION AND INJURY WITH CKD PROGRESSION, AND (3) DETERMINE WHETHER RANDOMIZATION TO INTENSIVE BLOOD PRESSURE MANAGEMENT ARM OF THE TRIAL SLOWS PROGRESSION OF KIDNEY TUBULAR DYSFUNCTION AND INJURY OVER TIME COMPARED WITH STANDARD BLOOD PRESSURE MANAGEMENT.
VETERANS MEDICAL RESEARCH FOUNDATION OF SAN DIEGO, WHERE WE HONOR SERVICE WITH SCIENCE, IS THE REGION'S ONLY MEDICAL RESEARCH INSTITUTE DEDICATED TO VETERANS. WE FACILITATE WORLD-CLASS RESEARCH AT THE VA SAN DIEGO HEALTHCARE SYSTEM THAT PROVIDES IMPROVEMENTS FOR VETERANS' HEALTHCARE. WHILE FOCUSED ON VETERANS, OUR MEDICAL ADVANCES EXTEND TO THE ENTIRE POPULATION AND RAISE THE STANDARD OF CARE FOR EVERYONE.
DR. GUATELLI-ENHANCEMENT OF INFECTIVITY BY HIV-1 VIA ANTAGONISM OF SERINC PROTEINS.THE PURPOSE OF THIS PROJECT IS TO 1) COMBINE OUR BIOCHEMICAL, CELL BIOLOGIC, AND VIROLOGIC ASSAYS TO VALIDATE AND ELABORATE THESE MECHANISMS 2) DETERMINE THE STRUCTURAL BASIS OF SERINC ANTAGONISM BY NEF. WE AIM TO PROVIDE HIGH-RESOLUTION STRUCTURES OF THE INTERACTION OF NEF WITH SERING PROTEINS AND CLATHRIN ADAPTORS. 3) DETERMINE HOW SERING PROTEINS AFFECT INFECTIVITY IN AN ENV-DEPENDENT MANNER. TO FACILITATE AN UNDERSTANDING OF SERINC FUNCTION, WE WILL CHARACTERIZE A FULL-LENGTH PROTEIN BIOPHYSICALLY AND AIM TO PROVIDE A HIGH-RESOLUTION STRUCTURE. WE WILL TEST THE HYPOTHESIS THAT SERINC PROTEINS INTERACT WITH ENV TO INHIBIT INFECTIVITY AND MAP THE INTERACTION. WE WILL DETERMINE WHETHER SERINC PROTEINS AFFECT THE CONFORMATION OF ENV TRIMERS AS DISPLAYED ON THE CELL SURFACE AND ON VIRIONS. LASTLY, WE WILL ELABORATE A MODEL IN WHICH THE CYTOPLASMIC DOMAIN OF ENV CONTRIBUTES TO COUNTERACTION OF SERING PROTEINS. WHEN THE PROPOSED EXPERIMENTS ARE COMPLETE, WE SHOULD HAVE A HIGH RESOLUTION MECHANISTIC UNDERSTANDING OF HOW NEF COUNTERACTS THE INHIBITORY INFLUENCE OF THE SERINC PROTEINS ON VIRAL INFECTIVITY, AND A MODEL FOR HOW THE ACTIVITY OF ENV IS INHIBITED BY THESE PROTEINS
DR. LANG MULTI-SITE FEASIBILITY OF COMPASSION MEDITATION FOR VETERANS WITH PTSD HE OVERALL GOAL OF THIS APPLICATION IS TO LEVERAGE AN EXISTING COMPASSION MEDITATION (CM) PROTOCOL TO DEVELOP THE COGNITIVELY BASED COMPASSION TRAINING (CBCT-VET) FOR VETERANS WITH PTSD. SPECIFICALLY, THIS PROJECT AIMS TO EXAMINE THE FEASIBILITY OF A MULTI-SITE TRIAL OF CBCT-VET COMPARED TO A RELAXATION CONTROL (VETERAN.CALM); DEVELOP PROCEDURES FOR THERAPIST TRAINING AND FIDELITY MONITORING; AND, PILOT TEST MULTI-MODAL ASSESSMENT PROCEDURES. IF SUCCESSFUL, THIS PROJECT COULD INFORM THE STUDY DESIGN OF A FUTURE LARGER-SCALE RCT MULTI- SITE EFFICACY STUDY AND CONTRIBUTE TO THE KNOWLEDGE BASE OF NON-PHARMACOLOGICAL BEHAVIORAL APPROACHES FOR PTSD IN UNDERTREATED VETERANS, A SIGNIFICANT PUBLIC HEALTH CONCERN.
Name (title) | Role | Hours | Compensation |
---|---|---|---|
Pete Hekman Vadm Usn Ret Vice Chairman | OfficerTrustee | 1 | $0 |
Phillip L Jelsma ESQ Chairman | OfficerTrustee | 4 | $55,000 |
Kathleen Kim MD Director | Trustee | 1 | $0 |
Robin Sami ESQ Director | Trustee | 1 | $0 |
Robert B Halder MD Radm Usn Ret Director | Trustee | 1 | $0 |
Paul Pearigen MD Rdml Usn Ret Director | Trustee | 1 | $0 |
Vendor Name (Service) | Service Year | Compensation |
---|---|---|
Regents Of The University Of California Lab Services | 9/29/22 | $218,093 |
Proteas Bioanalytics Lab Services | 9/29/22 | $121,899 |
Statement of Revenue | |
---|---|
Federated campaigns | $0 |
Membership dues | $0 |
Fundraising events | $0 |
Related organizations | $0 |
Government grants | $11,253,161 |
All other contributions, gifts, grants, and similar amounts not included above | $242,856 |
Noncash contributions included in lines 1a–1f | $0 |
Total Revenue from Contributions, Gifts, Grants & Similar | $11,496,017 |
Total Program Service Revenue | $4,416,553 |
Investment income | $0 |
Tax Exempt Bond Proceeds | $0 |
Royalties | $0 |
Net Rental Income | $0 |
Net Gain/Loss on Asset Sales | $0 |
Net Income from Fundraising Events | $0 |
Net Income from Gaming Activities | $0 |
Net Income from Sales of Inventory | $0 |
Miscellaneous Revenue | $0 |
Total Revenue | $15,912,570 |
Statement of Expenses | |
---|---|
Grants and other assistance to domestic organizations and domestic governments. | $0 |
Grants and other assistance to domestic individuals. | $0 |
Grants and other assistance to Foreign Orgs/Individuals | $0 |
Benefits paid to or for members | $0 |
Compensation of current officers, directors, key employees. | $679,510 |
Compensation of current officers, directors, key employees. | $679,510 |
Compensation to disqualified persons | $0 |
Other salaries and wages | $9,054,923 |
Pension plan accruals and contributions | $293,857 |
Other employee benefits | $581,956 |
Payroll taxes | $492,225 |
Fees for services: Management | $0 |
Fees for services: Legal | $25,839 |
Fees for services: Accounting | $54,300 |
Fees for services: Lobbying | $1,425 |
Fees for services: Fundraising | $0 |
Fees for services: Investment Management | $0 |
Fees for services: Other | $3,182,482 |
Advertising and promotion | $0 |
Office expenses | $0 |
Information technology | $0 |
Royalties | $0 |
Occupancy | $8,946 |
Travel | $16,064 |
Payments of travel or entertainment expenses for any federal, state, or local public officials | $36,148 |
Conferences, conventions, and meetings | $0 |
Interest | $0 |
Payments to affiliates | $0 |
Depreciation, depletion, and amortization | $47,937 |
Insurance | $302,216 |
All other expenses | $161,960 |
Total functional expenses | $16,424,334 |
Balance Sheet | |
---|---|
Cash—non-interest-bearing | $727,290 |
Savings and temporary cash investments | $0 |
Pledges and grants receivable | $1,177,473 |
Accounts receivable, net | $3,591,508 |
Loans from Officers, Directors, or Controlling Persons | $0 |
Loans from Disqualified Persons | $0 |
Notes and loans receivable | $4,509 |
Inventories for sale or use | $0 |
Prepaid expenses and deferred charges | $244,493 |
Net Land, buildings, and equipment | $437,997 |
Investments—publicly traded securities | $0 |
Investments—other securities | $0 |
Investments—program-related | $0 |
Intangible assets | $0 |
Other assets | $45,923 |
Total assets | $6,229,193 |
Accounts payable and accrued expenses | $3,302,233 |
Grants payable | $0 |
Deferred revenue | $1,278,573 |
Tax-exempt bond liabilities | $0 |
Escrow or custodial account liability | $0 |
Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
Secured mortgages and notes payable | $0 |
Unsecured mortgages and notes payable | $0 |
Other liabilities | $0 |
Total liabilities | $4,580,806 |
Net assets without donor restrictions | $1,561,929 |
Net assets with donor restrictions | $86,458 |
Capital stock or trust principal, or current funds | $0 |
Paid-in or capital surplus, or land, building, or equipment fund | $0 |
Retained earnings, endowment, accumulated income, or other funds | $0 |
Total liabilities and net assets/fund balances | $6,229,193 |